Could Retatrutide Trigger the Next Wave of Demand for Peptide APIs? From blockbuster obesity drugs to peptide manufacturing: why the industry is watch

By:DengYue International Business Division

For many people struggling with weight loss, “eat less and move more” is often easier said than done. Weight management is rarely just a matter of willpower. It is closely connected to metabolism, hormones, lifestyle, and long-term health conditions.

Over the past few years, the obesity treatment landscape has changed dramatically.

The introduction of GLP-1 receptor agonists represented by semaglutide reshaped expectations around medical weight management. Later, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide raised the bar again and rapidly became one of the most influential products in the market.

Now, attention is turning toward the next generation of obesity therapies.

On May 21, 2026, Eli Lilly announced positive topline results from its Phase 3 TRIUMPH-1 study evaluating Retatrutide, an investigational GCG/GIP/GLP-1 triple receptor agonist.

Although Retatrutide has not yet received regulatory approval and remains in clinical development, its latest results have drawn considerable attention across both the pharmaceutical and peptide manufacturing industries.

Retatrutide Phase 3 Results: Weight Reduction Exceeding 30%

The TRIUMPH-1 study evaluated Retatrutide in adults with obesity or overweight and at least one weight-related comorbidity, excluding diabetes.

At week 80, all treatment groups reached both primary and key secondary endpoints with clinically meaningful weight reduction.

Key findings included:

4 mg dose

● Average body weight reduction: 19.0%

● Average weight loss: 47.2 lbs

9 mg dose

● Average body weight reduction: 25.9%

● Average weight loss: 64.4 lbs

12 mg dose

● Average body weight reduction: 28.3%

● Average weight loss: 70.3 lbs

Even more notably, in a predefined extension involving patients with BMI ≥35:

Participants receiving 12 mg treatment through week 104 achieved an average weight reduction of 30.3%.

Historically, weight reduction at this level has typically been associated with bariatric surgery.

In addition to weight reduction, Retatrutide also demonstrated improvements in several cardiometabolic markers, including:

● Waist circumference

● Non-HDL cholesterol

● Triglycerides

● Systolic blood pressure

● High-sensitivity C-reactive protein (hsCRP)

These results suggest that the therapy may potentially affect broader metabolic health indicators beyond body weight alone.

Why Is Retatrutide Receiving So Much Attention?

The answer may lie in its mechanism of action.

Earlier therapies focused on one or two pathways:

Semaglutide

GLP-1 receptor agonist

Tirzepatide

GLP-1 + GIP dual agonist

Retatrutide

GLP-1 + GIP + Glucagon receptor agonist

By activating multiple metabolic pathways simultaneously, Retatrutide aims not only to suppress appetite but also to regulate energy expenditure and fat metabolism.

This triple-agonist strategy is one reason why many researchers consider it a potential next-generation obesity therapy.

However, for the broader industry, another question may be even more important:

What happens upstream if these therapies reach large-scale commercialization?

The Next Competition May Be Happening in Peptide Supply Chains

The rapid rise of semaglutide and tirzepatide already revealed several challenges across the industry:

● Peptide API shortages

● Manufacturing bottlenecks

● Limited CDMO capacity

● Extended production timelines

● Supply-demand imbalance

As more pharmaceutical companies move into obesity and metabolic disease pipelines, demand for peptide-based therapeutics continues to grow.

Today, many global pharmaceutical and biotechnology companies are actively developing:

● Triple agonists

● Long-acting obesity therapies

● Oral GLP-1 products

● Combination metabolic therapies

This trend suggests that the future obesity market may not be driven only by clinical innovation.

It may also depend heavily on scalable peptide manufacturing capacity.

China's Growing Role in GLP-1 and Peptide Manufacturing

Over recent years, China has significantly expanded its capabilities in peptide-related manufacturing.

Areas of growth include:

● Large-scale peptide synthesis

● GLP-1 related peptide APIs

● Process development

● CDMO manufacturing support

● Commercial-scale production

As global pharmaceutical companies continue diversifying supply chains, Chinese peptide manufacturing capacity is becoming increasingly important within international markets.

The discussion is gradually shifting from:

"Who has the next blockbuster obesity drug?"

to:

"Who can reliably manufacture it at scale?"

How DengYueMed Supports Peptide Supply Needs

At DengYueMed, we closely follow the rapidly evolving obesity therapeutic landscape and peptide manufacturing ecosystem.

Our areas of focus include:

✓ Peptide APIs and raw materials

✓ GLP-1 related peptide products

✓ Supply chain support

✓ Global pharmaceutical partnerships

As next-generation obesity therapies continue advancing, upstream peptide manufacturing may become a critical component of future pharmaceutical innovation.

The next wave of competition may begin long before products reach patients.

Disclaimer: Retatrutide is an investigational drug candidate currently in clinical development and has not yet received regulatory approval. This article is for informational purposes only and does not constitute medical advice.